KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Raw Materials (2016 - 2019)

Jazz Pharmaceuticals has reported Raw Materials over the past 10 years, most recently at $7.1 million for Q1 2019.

  • Quarterly Raw Materials changed N/A to $7.1 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Mar 2019, changed N/A year-over-year, with the annual reading at $5.6 million for FY2018, 58.22% up from the prior year.
  • Raw Materials was $7.1 million for Q1 2019 at Jazz Pharmaceuticals, up from $5.6 million in the prior quarter.
  • Over five years, Raw Materials peaked at $7.1 million in Q1 2019 and troughed at $1.5 million in Q4 2016.
  • The 5-year median for Raw Materials is $2.7 million (2016), against an average of $3.6 million.
  • Biggest five-year swings in Raw Materials: plummeted 40.68% in 2016 and later skyrocketed 128.96% in 2017.
  • Tracing JAZZ's Raw Materials over 5 years: stood at $2.6 million in 2015, then plummeted by 40.68% to $1.5 million in 2016, then soared by 128.96% to $3.5 million in 2017, then surged by 58.22% to $5.6 million in 2018, then increased by 27.37% to $7.1 million in 2019.
  • According to Business Quant data, Raw Materials over the past three periods came in at $7.1 million, $5.6 million, and $4.2 million for Q1 2019, Q4 2018, and Q2 2018 respectively.